We have been representing patients and their family in drug injury lawsuits for the past 15 years and this is our main practice area.
Drug injury legal compensation cases involve personal injury or wrongful death claims filed on behalf of people who, unfortunately, experienced a serious side effect, had an adverse drug reaction, or died from their use of a prescription medication.
Given our many years of experience handling these types of lawsuits we know drug injury cases deserve special attention.
Drug injury claims have a personal aspect which must be appreciated and respected by the attorney handling your case. At our law firm, we do not underestimate nor lose sight of the trust which is being placed in us by clients when they select us to represent them for their lawsuit against the responsible pharmaceutical company.
We will handle your drug injury case not only competently and professionally, but with genuine care and understanding. Any inquiries from our clients are responded to promptly, and telephone calls are always returned without delay.
If you, relatives, or friends need legal advice or legal representation for a personal injury lawsuit or a wrongful death lawsuit involving a drug side effect, the Law Offices of Thomas J. Lamb is here to help.
We encourage you to submit a Drug Injury Law Case Review — it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, or some other lawyer — about your case based on his many years of experience.
We handle these drug injury cases on a contingency fee basis, meaning that there is no payment for our legal services until we are successful in getting legal compensation for you.
While our office is in Wilmington, North Carolina, we have successfully handled drug injury lawsuits for people all over the United States.
It is important to note that we do not put our clients into large class actions. Rather we favor an individual lawsuit approach, which allows us to give personal attention to each of our clients, from start to finish.
Legal & Medical News: Featured Article
In a November 9, 2015 news report, “Antithrombotics Have Varied Risk of Causing Major Bleeds”, there is a summary of one presentation the American Heart Association 2015 Scientific Sessions:
Clot-busting drugs work, but they sometimes cause dangerous major bleeding. Reporting at the American Heart Association 2015 Scientific Sessions in Orlando, FL, a team of drug company researchers offered results of a retrospective cohort study showing that apixaban (Eliquis/Bristol-Myers-Squibb/Pfizer) had a lower risk of bleeding….
Compared to warfarin patients, those on [Eliquis (apixaban)] had about half the risk (HR=0.53) of a major bleed. The research is presented in [“Abstract 18465: Real World Comparison of Major Bleeding Risk Among Non-valvular Atrial Fibrillation Patients Newly Initiated on Warfarin versus Apixaban 5mg BID, Dabigatran 150 mg BID, or Rivaroxaban 20 mg QD.”]
It seems from the summary report of this presentation that the pharmaceutical companies responsible for Eliquis were seeking to distinguish their blood thinner medicine from Pradaxa, Xarelto, and Savaysa. All of these medicines are in the non-vitamin K antagonist oral anticoagulants (NOACs) class of drugs.
But when it comes to there being a specific reversal agent to stop an acute bleed once it start, Eliquis, Xarelto, and Savaysa share the dubious distinction of not currently having one that is FDA-approved for use. For more about this unfortunate and unsafe situation, see this recent article, “Still No Approved Reversal Agents Or Antidotes For Eliquis, Savaysa, And Xarelto To Stop Acute Bleeding”, which has this sub-headline: None Available To Help Patients Who Undergo Emergency Surgery Or When There Is Life-Threatening Uncontrolled Bleeding.
Only Pradaxa has a so-called antidote at the present time. In more detail, On October 16, 2015 the FDA granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.
- Zofran MDL Pending In Massachusetts With Judge Dennis Saylor Presiding
- Hep C Drugs Viekira Pak And Technivie: FDA Warnings About Liver Injury
- October 2015 Update On Bayer’s YAZ / Yasmin Settlement Program Numbers
- Xarelto / Savaysa / Pradaxa / Eliquis: Effect Of Platelet Inhibitors
- No Antidotes For Eliquis, Savaysa, And Xarelto To Stop Acute Bleeding
- Invokana Label Gets New Warnings About Increased Bone Fracture Risks
- Merck Fosamax – Femur Fracture Lawsuits Wait For Appeals Court Rulings
- After PML Warnings, Gilenya Has Cancer Side Effects Says Health Canada